openPR Logo
Press release

Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

05-19-2024 08:29 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Endometrial Cancer Pipeline

Endometrial Cancer Pipeline

DelveInsight's, "Endometrial Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Endometrial Cancer Pipeline Report
• DelveInsight's Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Endometrial Cancer treatment.
• The leading Endometrial Cancer Companies working in the market include Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Promising Endometrial Cancer Therapies in the various stages of development include TSR-042, Sacituzumab Govitecan, Olaparib, Ataluren + Pembrolizumab, Fulvestrant, and others.
• May 2024:- Karyopharm Therapeutics Inc- A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma. The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy.
• May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095).
• May 2024:- Kartos Therapeutics Inc.- A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.

Request a sample and discover the recent advances in Endometrial Cancer @ Endometrial Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometrial Cancer Overview
Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly.

The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body. Endometrial cancer is a type of cancer that begins as a growth of cells in the uterus. The uterus is the hollow, pear-shaped pelvic organ where fetal development happens. Endometrial cancer begins in the layer of cells that form the lining of the uterus, called the endometrium. Endometrial cancer is sometimes called uterine cancer.

Endometrial Cancer Emerging Drugs Profile

• LENVIMA: Merck & Co
Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.

• Mirvetuximab soravtansine: ImmunoGen
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.

• XMT 1660: Mersana Therapeutics
XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.

• VLS-1488: Volastra Therapeutics, Inc.
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra's innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.

Learn more about Endometrial Cancer in clinical trials @ Endometrial Cancer Drugs- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometrial Cancer Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. Phase III include Merck & Co.

DelveInsight's Endometrial Cancer Pipeline Report covers around 50+ products under different phases of clinical development like
• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Endometrial Cancer in development @ Endometrial Cancer Clinical Trials- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometrial Cancer Companies
Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Endometrial Cancer Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies

To know more about Endometrial Cancer, visit @ Endometrial Cancer Segmentation- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Endometrial Cancer Pipeline Report
• Coverage- Global
• Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Endometrial Cancer Therapies- TSR-042, Sacituzumab Govitecan, Olaparib, Ataluren + Pembrolizumab, Fulvestrant, and others.

For further information on the Endometrial Cancer Pipeline Therapeutics, reach out @ Endometrial Cancer Products Development- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometrial Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. LENVIMA: Merck & Co
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Mirvetuximab soravtansine: ImmunoGen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. VLS-1488: Volastra Therapeutics, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Endometrial Cancer Key Companies
21. Endometrial Cancer Key Products
22. Endometrial Cancer - Unmet Needs
23. Endometrial Cancer - Market Drivers and Barriers
24. Endometrial Cancer - Future Perspectives and Conclusion
25. Endometrial Cancer Analyst Views
26. Endometrial Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here

News-ID: 3502529 • Views:

More Releases from DelveInsight Business Research

Chronic Wounds Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), | DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE
Chronic Wounds Market is Predicted to Exhibit Remarkable Growth During the Forec …
The Chronic Wounds market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Wounds pipeline products will significantly revolutionize the Chronic Wounds market dynamics. DelveInsight's "Chronic Wounds Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States,
Influenza A Infections Market 2032: Epidemiology Trends, Innovative Therapies, Regulatory Approvals by DelveInsight | Valenta Pharm JSC, Pneumagen, ModernaTX, Janssen Research & Development, LLC, Ainos, Inc., Genentech, Inc., TaiGen Biotechnology Co., Ltd
Influenza A Infections Market 2032: Epidemiology Trends, Innovative Therapies, R …
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics. DelveInsight's "Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A
EGFR-Non Small Cell Lung Cancer Market 2032: Epidemiology Review, Pipeline Breakthroughs, Regulatory Highlights by DelveInsight | Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo
EGFR-Non Small Cell Lung Cancer Market 2032: Epidemiology Review, Pipeline Break …
DelveInsight's "Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Epidermal growth factor receptor-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Epidermal growth factor receptor-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Epidermal growth
Candidemia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, Regulatory Updates by DelveInsight | Cidara Therapeutics, Mundipharma, Pfizer
Candidemia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, R …
The Candidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Candidemia pipeline products will significantly revolutionize the Candidemia market dynamics. DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,

All 5 Releases


More Releases for Endometrial

Endometrial Biopsy Catheter Market 2022 | Detailed Report
Global Endometrial Biopsy Catheter Market 2022-2028, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5389813 The report provides
Endometrial Ablation Market Future Outlook 2021-2030
The Global Endometrial Ablation Market size is estimated to be USD 0.97 billion in 2019 and is predicted to reach USD 1.71 billion by 2030 with a CAGR of 5.3% from 2020-2030. Endometrial Ablation is a procedure which involves the removal of endometrium, the outer layer of uterus to treat the excessive blood flow during It is one of the mostly used non invasive procedure to treat uterine bleeding, prolong
Endometrial Biopsy Catheter Market Technological Breakthroughs
Perimenopausal and postmenopausal (absence of menstruation for 12 months or longer) women usually come across problems of abnormal uterine bleeding. Endometrial biopsy is a safe and efficient procedure for sampling the endometrium in a patient experiencing abnormal uterine bleeding to diagnose the condition and provide appropriate treatment. An endometrial suction catheter is used to carry out the biopsy. Endometrial biopsy catheters are easy to use, and have diagnostic accuracy which
Endometrial Ablation Market Growth Analysis 2024
TMR estimates that the global market for endometrial ablation will exhibit a promising CAGR of 5.50% from 2016 to 2024, rising from an opportunity worth US$0.8 bn in 2015 to US$1.3 bn by 2024. Rising Rate of Incidence of Gynecological Diseases to Drive Market The market is expected to benefit from a number of factors, which will be seen in its steady growth path over the course of the report’s forecast. The
Endometrial Ablation Market snapshot 2024
Global Endometrial Ablation Market: Snapshot With the rising prevalence of gynecology disorders, such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, the global adoption of endometrial ablation procedures has increased significantly, leading to an impressive rise in the worldwide endometrial ablation market. Apart from this, the upswing in the incidence rate of cervical and endometrial cancer in women is also driving the growth of this market substantially across the world. Download The
Global Endometrial Ablation Market: Radiofrequency Endometrial Ablation Devices …
With the presence of large players, such as Hologic Corp., Boston Scientific Corp., Cooper Surgical Inc., Ethicon Inc., and Medtronic Plc at the global level, the worldwide market for endometrial ablation demonstrates a highly competitive landscape, finds a new research report by Transparency Market Research (TMR). The market players are focusing aggressively on developing their offerings technologically, which is likely to lead to price differentiation, resulting in intense rivalry between these